Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma

References

• Lukes R J, Butler J J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063–1083
   PubMed Web of Science ®Google Scholar
• Küppers R. Identifying the precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease: role of the germinal center in B-cell lymphomagenesis. J Acquir Immune Defic Syndr 1999; 21(Suppl 1)S74–S79
   PubMed Web of Science ®Google Scholar
• Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98: 762–770
   PubMed Web of Science ®Google Scholar
• Bargou R C, Emmerich F, Krappmann D, Bommert K, Mapara M Y, Arnold W, Royer H D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961–2969
   PubMed Web of Science ®Google Scholar
• Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Greenblatt M S, Bennett W P, Hollstein M, Harris C C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4878
   PubMed Web of Science ®Google Scholar
• Masuda H, Miller C, Koeffler H P, Battifora H, Cline M J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc Natl Acad Sci USA 1987; 84: 7716–7719
   PubMed Web of Science ®Google Scholar
• Slebos R J, Resnick M A, Taylor J A. Inactivation of the p53 tumor suppressor gene via a novel Alu rearrangement. Cancer Res 1998; 58: 5333–5336
   PubMed Web of Science ®Google Scholar
• Küpper M, Joos S, von Bonin F, Daus H, Pfreundschuh M, Lichter P, Trumper L. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed – Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 2001; 112: 768–775
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Roers A, Kuppers R, Rajewsky K, Hansmann M L. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed – Sternberg cells in Hodgkin's disease. Blood 1999; 94: 1755–1760
   PubMed Web of Science ®Google Scholar
• Trümper L H, Brady G, Bagg A, Gray D, Loke S L, Griesser H, et al. Single-cell analysis of Hodgkin and Reed – Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 1993; 81: 3097–3115
   PubMed Web of Science ®Google Scholar
• Garcia J F, Villuendas R, Sanchez-Beato M, Sanchez-Aguilera A, Sanchez L, Prieto I, Piris M A. Nucleolar p14ARF overexpression in Reed – Sternberg cells in Hodgkin's lymphoma: absence of p14ARF/Hdm2 complexes is associated with expression of alternatively spliced Hdm2 transcripts. Am J Pathol 2002; 160: 569–578
   PubMed Web of Science ®Google Scholar
• Maggio E M, Stekelenburg E, Van den Berg A, Poppema S. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. Int J Cancer 2001; 94: 60–66
   PubMed Web of Science ®Google Scholar
• Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, et al. Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood 1994; 84: 4295–4300
   PubMed Web of Science ®Google Scholar
• Diehl V, Kirchner H H, Burrichter H, Stein H, Fonatsch C, Gerdes J, et al. Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep 1982; 66: 615–632
   PubMedGoogle Scholar
• Kanzler H, Hansmann M L, Kapp U, Wolf J, Diehl V, Rajewsky K, Kuppers R. Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line L1236 from the Hodgkin/Reed – Sternberg cells of a Hodgkin's lymphoma patient. Blood 1996; 87: 3429–3436
   PubMed Web of Science ®Google Scholar
• Freedman D A, Epstein C B, Roth J C, Levine A J. A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 1997; 3: 248–259
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Serpi R, Rahkolin M, Vahakangas K. Comparison of anti-p53 antibodies in immunoblotting. Biochem Biophys Res Commun 2002; 293: 850–856
   PubMed Web of Science ®Google Scholar
• Gupta R K, Patel K, Bodmer W F, Bodmer J G. Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease. Proc Natl Acad Sci USA 1993; 90: 2817–2821
   PubMed Web of Science ®Google Scholar
• Cho Y, Gorina S, Jeffrey P D, Pavletich N P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346–355
   PubMed Web of Science ®Google Scholar
• Martin A C, Facchiano A M, Cuff A L, Hernandez-Boussard T, Olivier M, Hainaut P, Thornton J M. Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat 2002; 19: 149–164
   PubMed Web of Science ®Google Scholar
• Kolomietz E, Meyn M S, Pandita A, Squire J A. The role of Alu repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes Cancer 2002; 35: 97–112
   PubMed Web of Science ®Google Scholar
• Courtois S, Verhaegh G, North S, Luciani M G, Lassus P, Hibner U, et al. DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002; 21: 6722–6728
   PubMed Web of Science ®Google Scholar
• Yin Y, Stephen C W, Luciani M G, Fahraeus R. p53 stability and activity is regulated by Mdm2-mediated induction of alternative translation products. Nat. Cell Biol 2002; 4: 462–467
   PubMed Web of Science ®Google Scholar
• Ray P S, Grover R, Das S. Two internal ribosome entry sites mediate the translation of p53 isoforms. EMBO Rep 2006, Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Dittmer D, Pati S, Zambetti G, Chu S, Teresky A K, Moore M, et al. Gain of function mutations in p53. Nat Genet 1993; 4: 42–46
   PubMed Web of Science ®Google Scholar
• Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine A J. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci USA 1996; 93: 4781–4786
   PubMed Web of Science ®Google Scholar
• Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman L A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997; 185: 833–841
   PubMed Web of Science ®Google Scholar
• Sanchez-Beato M, Sanchez-Aguilera A, Piris M A. Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101: 1220–1235
   PubMed Web of Science ®Google Scholar
• Olivier M, Eeles R, Hollstein M, Khan M A, Harris C C, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607–614
   PubMed Web of Science ®Google Scholar